# A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07827261/  
OnCo record `nct07827261` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of izalontamab brengitecan and glecirasib in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07827261 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 36 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1; Glecirasib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Patients with locally advanced or metastatic non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07827261
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 for Injection Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07827261: https://clinicaltrials.gov/study/NCT07827261

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07827261.json